626 related articles for article (PubMed ID: 10694407)
1. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
2. Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker.
Slon-Usakiewicz JJ; Purisima E; Tsuda Y; Sulea T; Pedyczak A; Féthière J; Cygler M; Konishi Y
Biochemistry; 1997 Nov; 36(44):13494-502. PubMed ID: 9354617
[TBL] [Abstract][Full Text] [Related]
3. Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres.
Steinmetzer T; Zhu BY; Konishi Y
J Med Chem; 1999 Aug; 42(16):3109-15. PubMed ID: 10447955
[TBL] [Abstract][Full Text] [Related]
4. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
5. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
Su Z; Vinogradova A; Koutychenko A; Tolkatchev D; Ni F
Protein Eng Des Sel; 2004 Aug; 17(8):647-57. PubMed ID: 15358856
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.
Zdanov A; Wu S; DiMaio J; Konishi Y; Li Y; Wu X; Edwards BF; Martin PD; Cygler M
Proteins; 1993 Nov; 17(3):252-65. PubMed ID: 8272424
[TBL] [Abstract][Full Text] [Related]
7. NMR determination of pKa values for Asp, Glu, His, and Lys mutants at each variable contiguous enzyme-inhibitor contact position of the turkey ovomucoid third domain.
Song J; Laskowski M; Qasim MA; Markley JL
Biochemistry; 2003 Mar; 42(10):2847-56. PubMed ID: 12627950
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
9. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
[TBL] [Abstract][Full Text] [Related]
10. New bivalent thrombin inhibitors with N(alpha)(methyl)arginine at the P1-position.
Steinmetzer T; Batdordshjin M; Pineda F; Seyfarth L; Vogel A; Reissmann S; Hauptmann J; Stürzebecher J
Biol Chem; 2000 Jul; 381(7):603-10. PubMed ID: 10987367
[TBL] [Abstract][Full Text] [Related]
11. Nonpolar interactions of thrombin and its inhibitors at the fibrinogen recognition exosite: thermodynamic analysis.
Cheng Y; Slon-Usakiewicz JJ; Wang J; Purisima EO; Konishi Y
Biochemistry; 1996 Oct; 35(40):13021-9. PubMed ID: 8855937
[TBL] [Abstract][Full Text] [Related]
12. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors.
Tsuda Y; Cygler M; Gibbs BF; Pedyczak A; Féthière J; Yue SY; Konishi Y
Biochemistry; 1994 Dec; 33(48):14443-51. PubMed ID: 7981204
[TBL] [Abstract][Full Text] [Related]
13. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
14. Variability of the canonical loop conformations in serine proteinases inhibitors and other proteins.
Apostoluk W; Otlewski J
Proteins; 1998 Sep; 32(4):459-74. PubMed ID: 9726416
[TBL] [Abstract][Full Text] [Related]
15. The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.
Friedrich R; Steinmetzer T; Huber R; Stürzebecher J; Bode W
J Mol Biol; 2002 Mar; 316(4):869-74. PubMed ID: 11884127
[TBL] [Abstract][Full Text] [Related]
16. Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1', P2', and P3' substrate residues.
Martin PD; Malkowski MG; DiMaio J; Konishi Y; Ni F; Edwards BF
Biochemistry; 1996 Oct; 35(40):13030-9. PubMed ID: 8855938
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y
Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736
[TBL] [Abstract][Full Text] [Related]
18. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
Ganesh V; Lee AY; Clardy J; Tulinsky A
Protein Sci; 1996 May; 5(5):825-35. PubMed ID: 8732754
[TBL] [Abstract][Full Text] [Related]
20. A kinetic comparison of the homologous proteases astacin and meprin A.
Wolz RL
Arch Biochem Biophys; 1994 Apr; 310(1):144-51. PubMed ID: 8161197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
